This is the most recent cystic fibrosis assessment. To see the previous cystic fibrosis assessment, click here.
ICER’s report will focus on elexacaftor/tezacaftor/ivacaftor (Vertex Pharmaceuticals). ICER also will examine any new data that has become available since its May 2018 review of three other CF treatments already approved by the FDA: tezacaftor/ivacaftor (Symdeko®, Vertex), lumacaftor/ivacaftor (Orkambi®, Vertex), and ivacaftor (Kalydeco®, Vertex).
The California Technology Assessment Forum (CTAF) will convene to deliberate and vote on evidence presented in ICER's report on treatments for cystic fibrosis.
ASSOCIATED MEETING & MATERIALS
University of Missouri-St. Louis
Century BC Room, Millennium Student Center
1 University Boulevard
St. Louis, MO 63121
The Midwest CEPAC will convene to discuss treatments for cystic fibrosis.